
LB Pharmaceuticals rose 152.3% from $17.05 to $43.01, ahead of the S&P 500's +13.3%. Its worst day was Jan 12 (−8.2%), and its low came Nov 21 at $15.33.
Nov 17, 2025 – Nov 13, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
LB Pharmaceuticals closed at its lowest level of the year, 10.1% below where the year started.
−2.9% · S&P 500 +1.0%
LB Pharmaceuticals shares rose 15.4%, while the S&P 500 fell 0.3%.
+15.4%, the year's best day · S&P 500 −0.3%
Story events cover the past 12 months · Times ET
LB Pharmaceuticals shares rose 10.4%, while the S&P 500 rose 0.3%.
+10.4% · S&P 500 +0.3%
LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsych…
+12.7% · S&P 500 −1.2%
EPS of $-0.45 missed the $-0.37 estimate on $0.00 revenue.
−2.8% · S&P 500 −1.7%
EPS of $-0.67 beat the $-0.69 estimate on $0.00 revenue.
+3.8% · S&P 500 +0.6%
LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple
+11.6% · S&P 500 −1.5%
EPS of $-1.71 missed the $-0.81 estimate on $0.00 revenue.
−1.1% · S&P 500 −0.3%
LB Pharmaceuticals closed at its highest level of the year, 190.2% above where the year started.
+5.1% · S&P 500 +0.4%
EPS of $-1.79 missed the $-1.60 estimate on $0.00 revenue.
+10.3% · S&P 500 +0.3%
Where it ended: a close of $43.01 on Nov 13, 2026.
Nothing in the past 12 months.
All LBRX dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for LBRX and SPY from Benzinga historical bars. Not investment advice.